Nkarta (NKTX) Amortization of Deferred Charges (2019 - 2026)
Nkarta's (NKTX) quarterly Amortization of Deferred Charges came in at $544000.0 in Q1 2026, up 12.86% year-on-year from $482000.0 in Q1 2025, and up 4.02% quarter-over-quarter from $523000.0 in Q4 2025.
Nkarta (NKTX) Amortization of Deferred Charges (2019 - 2026) Analysis & Trends
Nkarta's Amortization of Deferred Charges history runs 8 years deep, the most recent figure standing at $544000.0 for Q1 2026.
- On a quarterly basis, Amortization of Deferred Charges rose 12.86% year-over-year to $544000.0 in Q1 2026; TTM through Mar 2026 was $2.0 million, a 7.49% decrease from a year earlier, with the FY2025 full-year figure at $2.0 million, down 14.65% from the prior year.
- Amortization of Deferred Charges rose to $544000.0 in Q1 2026 per NKTX's latest filing, from $523000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $1.4 million in Q1 2022 and bottomed at $456000.0 in Q2 2025.
- The 5-year median for Amortization of Deferred Charges is $561000.0 (2024), against an average of $643411.8.
- Across the five-year window, Amortization of Deferred Charges surged 1448.84% in 2022 and plunged 60.51% in 2023, its largest moves.
- Year by year, Amortization of Deferred Charges stood at $666000.0 in 2022, then dropped by 14.56% to $569000.0 in 2023, then dropped by 1.41% to $561000.0 in 2024, then decreased by 6.77% to $523000.0 in 2025, then climbed by 4.02% to $544000.0 in 2026.
- Per Business Quant, the three latest NKTX Amortization of Deferred Charges figures stand at $544000.0 (Q1 2026), $523000.0 (Q4 2025), and $490000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,290.43 Bn | 66,290.15 Bn | - |
| 2 | Nanobiotix | 1,914.07 Bn | 1,914.01 Bn | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - |
| 4 | BeOne Medicines | 467.97 Bn | 463.18 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.73 Bn | 115.48 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.42 Bn | 61.67 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.82 Bn | 62.82 Bn | - |
| 8 | Argenx Se | 56.00 Bn | 50.82 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.51 Bn | 34.50 Bn | 959.66 Mn |
| 10 | Nkarta | 174.51 Mn | 174.51 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 544,000.00 |
| Mar 31, 2026 | 544,000.00 |
| Dec 31, 2025 | 523,000.00 |
| Dec 31, 2025 | 523,000.00 |
| Sep 30, 2025 | 490,000.00 |
| Sep 30, 2025 | 490,000.00 |
| Jun 30, 2025 | 456,000.00 |
| Jun 30, 2025 | 456,000.00 |
| Mar 31, 2025 | 482,000.00 |
| Mar 31, 2025 | 482,000.00 |
| Dec 31, 2024 | 561,000.00 |
| Dec 31, 2024 | 561,000.00 |
| Sep 30, 2024 | 571,000.00 |
| Sep 30, 2024 | 571,000.00 |
| Jun 30, 2024 | 562,000.00 |
| Jun 30, 2024 | 562,000.00 |
| Mar 31, 2024 | 592,000.00 |
| Mar 31, 2024 | 592,000.00 |
| Dec 31, 2023 | 569,000.00 |
| Dec 31, 2023 | 569,000.00 |